NCT07702292招募中2 期
A Phase 2 Study of [68Ga]BED003 for PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 71
- 试验地点
- 7
- 主要终点
- Assess the diagnostic performance of [68Ga]BED003 in the peritoneum.
研究概览
简要总结
This is a multi-centre, open-label, single-arm, Phase 2 study designed to evaluate the diagnostic performance of [68Ga]BED003 in detecting colorectal cancer (CRC), gastric cancer (GC), pancreatic ductal adenocarcinoma (PDAC), invasive lobular breast cancer (ILC), and epithelial ovarian cancer (EOC).
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Diagnostic
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 79 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Participants provide informed consent and confirm that they are able and willing to comply with all protocol requirements.
- •Participants must be ≥ 18 years and < 80 years of age and competent to give informed consent.
- •Eastern Cooperative Oncology Group performance status ≤
- •Women of childbearing potential (WOCBP) must have a negative serum test at screening and a negative urine pregnancy test at the PET/CT imaging visit (Visit 2) prior to [68Ga]BED003 administration.
- •Note: If combining screening (Visit 1) and the PET/CT imaging visit (Visit 2) into a single visit, a serum pregnancy test must be used to exclude pregnancy.
- •WOCBP, and men who are sexually active with WOCBP, must agree to use a highly-effective method(s) of contraception from the PET/CT imaging visit (Day 1/Visit 2) to the safety follow-up telephone call (Day 3/Visit 3).
- •Diagnosis of either CRC (confirmed by histopathology), GC (confirmed by histopathology), PDAC (confirmed by cytology or histopathology), ILC (confirmed by histopathology), or EOC (suspected or confirmed by cytology or histopathology).
- •Note: Invasive breast cancer with mixed ductal/lobular histology is permitted.
- •Conventional imaging performed within 8 weeks of screening (Visit 1) and no later than 24 hours before [68Ga]BED003 administration and available for sending to the central imaging vendor, including, at a minimum, a contrast-enhanced CT that includes the abdomen and pelvis.
- •Treatment-naïve with at least stage IIB disease. Available biopsy sample or scheduled biopsy or surgical resection no later than Day
- •Cytology of the primary lesion is acceptable for participants with PDAC who are not surgical candidates.
- •Following neoadjuvant therapy (with at least stage IIB disease at initial presentation) with scheduled biopsy or surgical resection no later than Day
- •Suspected recurrence after definitive therapy.
排除标准
- •Participants administered any radioisotope within 5 physical half-lives prior to [68Ga]BED003 administration.
- •Participants administered any other IMP within 2 weeks or 5 half-lives, whichever is longest, prior to [68Ga]BED003 administration.
- •Participants who have recently received any other contrast agent (< 24 hours for IV agents and < 5 days for oral agents) before the day of [68Ga]BED003 administration.
- •Participants with a history of severe claustrophobia or panic attacks when in confined spaces.
- •Known hypersensitivity to [68Ga]BED003 or any of its constituents.
- •Participants with any medical condition or other circumstances at screening or in their past medical history that, in the opinion of the investigator, compromise obtaining reliable data, achieving study objectives, or study completion, including, but not limited to, the following:
- •Any other primary cancers that could confound the interpretation of the study results.
- •Major surgery (such as laparoscopy/laparotomy/thoracotomy) over the 3 months preceding screening that could confound the interpretation of the study results.
- •Serious, non-healing wound, ulcer, or bone fracture.
- •Active hepatitis.
- •Significant cardiac disorders including recent (in last 3 months) myocardial infarction or clinically significant electrocardiogram (ECG) findings.
- •Known diagnosis of an autoimmune or inflammatory disorder that is expected to confound image interpretation per investigator judgement, excluding disorders directly related to the index cancer (e.g. tumour-associated pancreatitis or biliary stasis for PDAC).
- •Medical history of abdomino-pelvic or breast irradiation in the last 3 months.
- •Presence of any current implanted foreign material (e.g. stents, surgical clips) that may confound image interpretation per investigator judgement.
- •Significant renal impairment, defined as an estimated glomerular filtration rate (as determined by the Modification of Diet in Renal Disease formula) below 45 mL/min/1.73m2 or a serum creatinine > 1.5 × the upper limit of normal.
- •Female participants who are breastfeeding, unless the participant commits to pumping breast milk and discarding it from from the PET/CT imaging visit (Day 1/Visit 2) to the safety follow-up telephone call (Day 3/Visit 3).
研究组 & 干预措施
[68Ga]BED003
Experimental
Each participant will receive [68Ga]BED003 followed by positron emission tomography (PET)/computed tomography (CT) imaging at the PET/CT imaging visit (Visit 2).
干预措施: [68Ga]BED003 (Drug)
结局指标
主要结局
Assess the diagnostic performance of [68Ga]BED003 in the peritoneum.
时间窗: Until completion of follow-up procedures, up to 42 days post injection.
Assess the diagnostic performance of \[68Ga\]BED003 in the peritoneum.
次要结局
- Further assess the diagnostic performance of [68Ga]BED003.(Until completion of follow-up procedures, up to 42 days post injection)
- Semiquantitative assessment of [68Ga]BED003 tumour uptake.(Immediately following administration of [68Ga]BED003)
- Evaluate the safety and tolerability of [68Ga]BED003.(From screening until safety follow-up (48 hours post injection).)
- Confirm optimal timing of imaging following [68Ga]BED003 injection (first 6 participants).(Immediately following administration of [68Ga]BED003)
- Confirm optimal [68Ga]BED003 administered activity (first 6 participants).(Immediately following administration of [68Ga]BED003)
研究者
研究点 (7)
Loading locations...
相似试验
招募中
2 期
A Study to Determine the Effectiveness of a Test Drug ([68Ga]BED003) for the Detection of Pancreatic, Colorectal, Gastric, Breast and Ovarian CancerColorectal cancer (CRC), gastric cancer (GC), pancreatic ductal adenocarcinoma (PDAC), invasive lobular breast cancer (ILC), and epithelial ovarian cancer (EOC).2025-521983-36-00Blue Earth Diagnostics Ireland Limited65
招募中
3 期
This Study Evaluates the Diagnostic Performance and Safety of 68Ga-NYM032 PET/CT Imaging in Patients With Suspected Recurrence of Prostate Cancer.Prostate CancerNCT07649122Norroy Bioscience Co., LTD232
招募中
2 期
[68Ga]Ga-FAPI total body PET/CT for improving diagnostic sensitivity and preoperative staging in gastroesophageal cancer and pancreatic cancer2023-503632-41-01Rigshospitalet
撤回
2 期
[68Ga]Ga-FAPI total body PET/CT for improving diagnostic sensitivity and preoperative staging in gastroesophageal cancer and pancreatic cancer2023-503632-41-00Rigshospitalet60
招募中
2 期
Exploratory study evaluating the relevance of [68Ga]Ga-FAPI-46 for staging and identifying progressing patients with transthyretin cardiac amyloidosisTransthyretin cardiac amyloidosis2025-523616-36-00Centre Hospitalier Universitaire De Nantes40